Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.

Autor: Matthias Scheffler, Thomas Zander, Lucia Nogova, Carsten Kobe, Deniz Kahraman, Markus Dietlein, Irini Papachristou, Lukas Heukamp, Reinhard Büttner, Ron Boellaard, Adriaan A Lammertsma, Silvia Querings, Erich Stoelben, Walburga Engel-Riedel, Bernd Neumaier, Jürgen Wolf

Publikováno v: PLoS ONE, Vol 8, Iss 1, p e53081 (2013)

3'-deoxy-3'-[(18)F]fluoro-L-thymidine (FLT) and 2'-deoxy-2'-[(18)F]fluoro-D-glucose (FDG) are used to visualize proliferative and metabolic activity of tumors. In this study we aimed at evaluating the prognostic value of FLT and FDG uptake measured b

Externí odkaz: https://doaj.org/article/ea9dfc6ca85d493eb465281389a28e09

Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [(18)F]Fluorodeoxyglucose and [(18)F]Fluorothymidine Positron Emission Tomography

Autor: Reinhard Buettner, Lukas C. Heukamp, Walburga Engel-Riedel, Thomas Zander, Egbert Smit, Irini Papachristou, Roman K. Thomas, Andreas H. Jacobs, Markus Dietlein, Karin Toepelt, Adriaan Lammertsma, Andreas Draube, Martin Hellmich, Juergen Wolf, Erich Stoelben, Matthias Scheffler, Silvia Querings, Roland T. Ullrich, Karin Schulte, Yon D. Ko, Carsten Kobe, Ronald Boellaard, Lucia Nogova, Michael Hallek, Bernd Neumaier, Andreas Schlesinger

Publikováno v: Zander, T, Scheffler, M, Nogova, L, Kobe, C, Engel-Riedel, W, Hellmich, M, Papachristou, I, Toepelt, K, Draube, A, Heukamp, L, Buettner, R, Ko, Y D, Ullrich, R T, Smit, E F, Boellaard, R, Lammertsma, A A, Hallek, M, Jacobs, A H, Schlesinger, A, Schulte, K, Querings, S, Stoelben, E, Neumaier, B, Thomas, R K, Dietlein, M & Wolf, J 2011, ' Early Prediction of Nonprogression in Advanced Non-Small-Cell Lung Cancer Treated With Erlotinib By Using [(18)F]Fluorodeoxyglucose and [(18)F]Fluorothymidine Positron Emission Tomography ', Journal of Clinical Oncology, vol. 29, no. 13, pp. 1701-1708 . https://doi.org/10.1200/JCO.2010.32.4939
Journal of Clinical Oncology, 29(13), 1701-1708. American Society of Clinical Oncology

Purpose Positron emission tomography (PET) with both 2′-deoxy-2′-[18F]fluoro-d-glucose (FDG) and 3′-[18F]fluoro-3′-deoxy-l-thymidine (FLT) was evaluated with respect to the accuracy of early prediction of nonprogression following erlotinib th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9604a21f24ac1acffe8e95f2c96803f
https://research.vumc.nl/en/publications/e2fdda8e-54e6-4f9c-afef-31a344e84680

SORAVE: Phase I study for the treatment of relapsed solid tumors with the combination of sorafenib and everolimus

Autor: Markus Dietlein, Ildiko Katay, Marc Bos, Noemi Muthen, Uwe Fuhr, Peter Mallmann, Matthias Scheffler, Max Schlaak, Fritz Soergel, Irini Papachristou, Roland Schnell, Deniz Kahraman, Juergen Wolf, Christian Mattonet, Masyar Gardizi, Lucia Nogova, Martina Kinzig, Carsten Kobe, Kerstin Rhiem, Denis Rokitta

Publikováno v: Journal of Clinical Oncology. 30:3044-3044

3044 Background: Dual inhibition of signaling pathways interfering with angiogenesis and cell proliferation may increase anti-tumor efficacy. We evaluated the combination of the VEGFR inhibitor sorafenib (S) and the mTOR inhibitor everolimus (E) and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1180460364e27d930ecef9ecbff74b8
https://doi.org/10.1200/jco.2012.30.15_suppl.3044

[18F]fluoro-L-thymidine (FLT) uptake in baseline positron emission tomography (PET) as a prognostic marker in patients with advanced non-small cell lung cancer (NSCLC) treated first-line with erlotinib

Autor: Irini Papachristou, Juergen Wolf, Carsten Kobe, Bernd Neumaier, Thomas Zander, Matthias Scheffler, Deniz Kahraman, Silvia Querings, Lucia Nogova, Markus Dietlein, Walburga Engel-Riedel, Erich Stoelben

Publikováno v: Journal of Clinical Oncology. 29:7591-7591

7591 Background: Since the introduction of targeted therapy into the treatment of advanced NSCLC molecular imaging tools gain in importance for assessment of pharmacodynamics, prognosis and predict...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4fa84291e1759688e0d20160b4548272
https://doi.org/10.1200/jco.2011.29.15_suppl.7591

SORAVE trial: Phase I sorafenib and everolimus in solid tumors

Autor: Christian Mattonet, Irini Papachristou, Juergen Wolf, Matthias Scheffler, Ildiko Katay, Lucia Nogova, Peter Mallmann, Uwe Fuhr, Markus Dietlein, R. Krais

Publikováno v: Journal of Clinical Oncology. 28:TPS170-TPS170

TPS170 Background: Clinical efficacy of the multikinase inhibitor sorafenib is mainly based on its antiangiogenic properties mediated by VEGFR inhibition. The mTOR inhibitor everolimus also exerts ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8e2800fb44745a881fa71b45e61f0e19
https://doi.org/10.1200/jco.2010.28.15_suppl.tps170